Natural course of low risk neuroblastoma

Pediatric Blood and Cancer

Volumn 58, Issue 5, 2012, Pages 690-694

  Shuangshoti, Somruetai ^a   Shuangshoti, Shanop ^b   Nuchprayoon, Issarang ^b   Kanjanapongkul, Somjai ^a   Marrano, Paula ^c   Irwin, Meredith S ^c,d,e   Thorner, Paul S ^b,c,e  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ganglioneuroma; MYCN oncogene; Neuroblastoma; Pediatric oncology; Thailand

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CANCER RISK; CHILD; DISEASE COURSE; FEMALE; GANGLIONEUROMA; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYCN GENE; NEUROBLASTOMA; ONCOGENE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THAILAND;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RISK; THAILAND;

EID: 84857852751     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23325     Document Type: Article

References (36)

1. Perez C, Matthay K, Atkinson J, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group study. J Clin Oncol 2000; 18: 18-26.
2. Maris J, Hogarty M, Bagatell R, et al. Neuroblastoma. Lancet 2007; 369: 2106-2120.
3. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23: 6459-6465.
4. Ross J, Davies S. Screening for neuroblastoma: Progress and pitfalls. Cancer Epidemiol Biomarkers Prev 1999; 8: 189-194.
5. Maris J, Matthay K. Molecular biology of neuroblastoma. J Clin Oncol 1999; 17: 2264-2279.
6. Riley R, Heney D, Jones D, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004; 10: 4-12.
7. Shimada H, Chatten J, Newton WJ, et al. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73: 405-416.
8. Brodeur G, Seeger R, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-1124.
9. Schwab M, Alitalo K, Klempnauer K, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 1983; 305: 245-248.
10. Seeger R, Brodeur G, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-1116.
11. Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010; 363: 1313-1323.
12. Katzenstein H, Bowman L, Brodeur G, et al. The prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group experience. J Clin Oncol 1998; 16: 2007-2017.
13. Bagatell R, Beck-Popovic M, London WB, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: A report from the International Neuroblastoma Risk Group database. J Clin Oncol 2009; 27: 365-370.
14. Ng S, Abdullah W, Lin H, et al. Presenting features and treatment outcome of 78 Malaysian children with neuroblastoma. Southeast Asian J Trop Med Public Health 1999; 30: 149-153.
15. Wiangnon S, Kamsa-Ard S, Jetsrisuparb A, et al. Childhood cancer in Thailand: 1995-1997. Asian Pac J Cancer Prev 2003; 4: 337-343.
16. Joseph V, Raj J. Experiences in the treatment of neuroblastoma. Ann Acad Med Singapore 1988; 17: 145-151.
17. Yong MH, Hwang WS, Knight LA, et al. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore. Singapore Med J 2009; 50: 1090-1094.
18. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
19. Joshi V. Peripheral neuroblastic tumors: Pathologic classification based on recommendations of international neuroblastoma pathology committee (Modification of shimada classification). Pediatr Dev Pathol 2000; 3: 184-199.
20. Thorner P, Ho M, Chilton-MacNeill S, et al. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections. Am J Surg Pathol 2006; 30: 635-642.
21. Bhargava R, Oppenheimer O, Gerald W, et al. Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH). An alternative and practical method. Diagn Mol Pathol 2005; 14: 72-76.
22. Korja M, Finne J, Salmi T, et al. Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas. Mod Pathol 2005; 18: 1599-1605.
23. Tsai H-Y, Hsi B-L, Hung I-J, et al. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: A chromogenic in situ hybridization study in paraffin sections. Hum Pathol 2004; 35: 1397-1403.
24. Hiyama E, Iehara T, Sugimoto T, et al. Effectiveness of screening for neuroblastoma at 6 months of age: A retrospective population-based cohort study. Lancet 2008; 371: 1173-1180.
25. Honjo S, Doran HE, Stiller CA, et al. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening. Int J Cancer 2003; 103: 538-543.
26. Henderson TO, Bhatia S, Pinto N, et al. Racial and ethnic disparities in risk and survival in children with neuroblastoma: A Children's Oncology Group Study. J Clin Oncol 2011; 29: 76-82.
27. Maris JM, Mosse YP, Bradfield JP, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008; 358: 2585-2593.
28. Kushner B, Cheung N, LaQuaglia M, et al. International neuroblastoma staging system stage 1 neuroblastoma: A prospective study and literature review. J Clin Oncol 1996; 14: 2174-2180.
29. Alvarado C, London W, Look A, et al. Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000; 22: 197-205.
30. Iwanaka T, Yamamoto K, Ogawa Y, et al. Maturation of mass-screened localized adrenal neuroblastoma. J Pediatr Surg 2001; 36: 1633-1636.
31. Nishihira H, Toyoda Y, Tanaka Y, et al. Natural course of neuroblastoma detected by mass screening: A 5-year prospective study at a single institution. J Clin Oncol 2000; 18: 3012-3017.
32. Oue T, Inoue M, Yoneda A, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: Results of the Wait and See pilot study. J Pediatr Surg 2005; 40: 359-363.
33. Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 1998; 16: 1265-1269.
34. Yoneda A, Oue T, Imura K, et al. Observation of untreated patients with neuroblastoma detected by mass screening: A "Wait and See" pilot study. Med Pediatr Oncol 2001; 36: 160-162.
35. Ijiri R, Tanaka Y, Kato K, et al. Clinicopathologic study of mass-screened neuroblastoma with special emphasis on untreated observed cases. A possible histologic clue to tumor regression. Am J Surg Pathol 2000; 24: 807-815.
36. Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009; 41: 718-723.